Physician profile
Stephen Holmes
NPI 1831132240
$13,392.37
in general payments reported to CMS, 2019-2025
31 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,415 · 2020: $2,254 · 2021: $2,435 · 2022: $1,267 · 2023: $1,839 · 2024: $2,030 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,021.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,183.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,826.13 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,755.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,470.23 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $1,083.41 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $780.52 | 2021-2025 | Freestyle Libre |
| Amgen INC. | $611.87 | 2019-2024 | Repatha, Prolia, Evenity |
| Allergan, INC. | $499.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $484.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $433.20 | 2021-2025 | Shingrix, Arexvy |
| Abbvie INC. | $327.27 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $295.04 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.27 | 2019-2021 | |
| Amarin Pharma, INC. | $178.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.31 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $173.86 | 2021 | |
| Dexcom, INC. | $167.63 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $136.99 | 2022-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $107.27 | 2020-2022 | |
| Exact Sciences Corporation | $104.39 | 2023-2024 | Cologuard Collection Kit |
| Genzyme Corporation | $85.79 | 2023-2025 | |
| Eisai INC. | $60.61 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $48.62 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $43.10 | 2023 | Contrave, Onzetra Xsail |
| Daiichi Sankyo INC. | $35.65 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $35.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.21 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.34 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.79 | 2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.